US 11,773,102 B2
Heterocyclic compounds as PI3K-γ inhibitors
Artem Shvartsbart, Kennett Square, PA (US); Stacey Shepard, Wilmington, DE (US); Andrew P. Combs, Kennett Square, PA (US); Lixin Shao, Wilmington, DE (US); Nikoo Falahatpisheh, Wilmington, DE (US); Ge Zou, Greenville, DE (US); Andrew W. Buesking, Wilmington, DE (US); Richard B. Sparks, Hockessin, DE (US); Eddy W. Yue, Landenberg, PA (US); and Ravi Kumar Jalluri, Avondale, PA (US)
Assigned to Incyte Corporation, Wilmington, DE (US)
Filed by Incyte Corporation, Wilmington, DE (US)
Filed on Jun. 24, 2021, as Appl. No. 17/356,984.
Application 16/589,523 is a division of application No. 16/045,358, filed on Jul. 25, 2018, granted, now 10,472,368, issued on Nov. 12, 2019.
Application 17/356,984 is a continuation of application No. 16/589,523, filed on Oct. 1, 2019, granted, now 11,091,491.
Application 16/045,358 is a continuation of application No. 15/343,375, filed on Nov. 4, 2016, granted, now 10,065,963, issued on Sep. 4, 2018.
Claims priority of provisional application 62/252,050, filed on Nov. 6, 2015.
Prior Publication US 2023/0009843 A1, Jan. 12, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61P 35/00 (2006.01); A61K 31/519 (2006.01); A61P 17/06 (2006.01); A61P 35/02 (2006.01); A61P 37/06 (2006.01); A61P 35/04 (2006.01); A61P 19/02 (2006.01); C07D 487/04 (2006.01); C07D 519/00 (2006.01)
CPC C07D 487/04 (2013.01) [A61K 31/519 (2013.01); A61P 17/06 (2018.01); A61P 19/02 (2018.01); A61P 35/00 (2018.01); A61P 35/02 (2018.01); A61P 35/04 (2018.01); A61P 37/06 (2018.01); C07D 519/00 (2013.01)] 27 Claims
 
1. A method of treating a disease or disorder associated with overexpression of PI3Kγ kinase, wherein the disease or disorder is selected from the group consisting of tumors, sarcomas, lymphomas, leukemias, lung cancer, melanoma, pancreatic cancer, breast cancer, prostate cancer, liver cancer, colon cancer, endometrial cancer, bladder cancer, skin cancer, cancer of the uterus, renal cancer, gastric cancer, myeloma, rheumatoid arthritis, multiple sclerosis, asthma, allergy, pancreatitis, psoriasis, anaphylaxis, glomerulonephritis, inflammatory bowel disease, thrombosis, meningitis, encephalitis, diabetic retinopathy, benign prostatic hypertrophy, myasthenia gravis, Sjögren's syndrome, osteoarthritis, restenosis, atherosclerosis, autoimmune hemolytic anemia, systemic lupus erythematosus, lupus nephritis, pemphigus, and inflammation, the method comprising administering to a patient in need thereof a therapeutically effective amount of a compound selected from:
2-amino-N-(1-[8-chloro-5-(2-methyl-1,1-dioxidothiomorpholin-4-yl)imidazo[1,5-a]pyridin-6-yl]ethyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide;
2-amino-N-{1-[8-chloro-1-cyano-5-(1,1-dioxidothiomorpholin-4-yl)imidazo[1,5-a]pyridin-6-yl]ethyl}pyrazolo[1,5-a]pyrimidine-3-carboxamide;
2-amino-N-(1-(8-chloro-1-cyano-5-(2-methyl-1,1-dioxidothiomorpholino)imidazo[1,5-a]pyridin-6-yl)ethyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; and
2-amino-N-(1-(8-chloro-1-cyano-5-(2-methyl-1,1-dioxidothiomorpholino)imidazo[1,5-a]pyridin-6-yl)propyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide;
or a pharmaceutically acceptable salt thereof.